KRYS
Krystal Biotech Inc
NASDAQ: KRYS · HEALTHCARE · BIOTECHNOLOGY
$259.95
-3.46% today
Updated 2026-04-29
Market cap
$7.65B
P/E ratio
38.06
P/S ratio
19.66x
EPS (TTM)
$6.83
Dividend yield
—
52W range
$123 – $298
Volume
0.3M
Krystal Biotech Inc (KRYS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.18M | $50.11M | $116.12M | $209.02M | $310.84M | $626.29M | $558.45M | $818.36M | $1.06B | $1.33B |
| Cash & equivalents | $1.92M | $49.59M | $103.67M | $187.51M | $268.27M | $341.25M | $161.90M | $358.33M | $344.87M | $496.30M |
| Current assets | $2.17M | $49.91M | $112.65M | $195.88M | $275.06M | $442.27M | $383.78M | $587.91M | $742.04M | $1.02B |
| Total liabilities | $1.89M | $640000.00 | $2.89M | $6.11M | $18.76M | $32.72M | $36.22M | $39.71M | $109.46M | $114.23M |
| Current liabilities | $43000.00 | $640000.00 | $2.60M | $3.33M | $15.45M | $25.74M | $28.85M | $33.09M | $102.00M | $102.94M |
| Long-term debt | $1.84M | $0.00 | — | — | — | — | — | — | — | — |
| Shareholder equity | $289000.00 | $49.47M | $113.23M | $202.91M | $292.08M | $593.58M | $522.23M | $778.64M | $946.38M | $1.22B |
| Retained earnings | $-1.15M | $-9.07M | $-19.96M | $-39.05M | $-71.21M | $-140.78M | $-280.76M | $-269.83M | $-180.67M | $24.16M |
| Accounts receivable | — | — | — | — | — | — | $0.00 | $42.04M | $104.75M | $127.42M |
| Inventory | — | $0.00 | — | — | — | — | $0.00 | $6.99M | $26.51M | $40.48M |
| Goodwill | — | $0.00 | — | — | — | — | — | — | — | — |